Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice

P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer

(2014) Sheida Shariat et al.   CANCER LETTERS

Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN

(2014) Mercedeh Mansourian et al.   IMMUNOLOGY LETTERS

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

(2013) Mariette I E van Poelgeest et al.   Journal of Translational Medicine

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

(2012) R Y Tsang et al.   BRITISH JOURNAL OF CANCER

Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis

(2012) Vahid Heravi Shargh et al.   VACCINE

Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists

(2011) Wenjun Meng et al.   BMC BIOTECHNOLOGY

CpG DNA as a vaccine adjuvant

(2011) Christian Bode et al.   Expert Review of Vaccines

Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles

(2011) Seyed Amir Jalali et al.   Nanomedicine-Nanotechnology Biology and Medicine

Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model

(2010) Nafiseh Pakravan et al.   CELL STRESS & CHAPERONES

Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy

(2009) Anahit Ghochikyan   CNS & Neurological Disorders-Drug Targets

Adoptive immunotherapy of cancer using CD4+ T cells

(2009) Pawel Muranski et al.   CURRENT OPINION IN IMMUNOLOGY

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

(2008) G. G. Kenter et al.   CLINICAL CANCER RESEARCH